HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine

Overview of attention for article published in Journal of Hematology & Oncology, April 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 6 X users

Readers on

mendeley: 13 Mendeley

Summary X

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 5,165 followers.

RT @NKcellBiology: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8(+) T and NK cells: a novel therapeut…

30 Apr 2021

Reply Repost Favourite

Therapeutic tumour vaccines based on double-activation of #CD8+ T and #NK cells. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8 + T and NK cells: a novel thera… https://t.co/KJHSNajKFb

30 Apr 2021

Reply Repost Favourite

HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8(+) T and NK cells: a novel therapeutic tumour vaccine https://t.co/sh68zZba6C

30 Apr 2021

Reply Repost Favourite

HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine: CONCLUSIONS: LA-induced immune antitumour activity through DC cross-activation with CD8^(+) T and NK cells, which… http

29 Apr 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.